South Africa: The Tightening Of The Noose

Last Updated: 20 August 2012
Article by Neil Kirby

The Minister of Health has published certain proposed amendments to the so-called Medicine Pricing Regulations for public comment in the Government Gazette on 6 July 2012. The amendments are primarily designed to amend the Regulations dealing with the single exit prices applicable to medicines and Scheduled substances in the Republic. The current set of regulations is available for public comment until 6 September 2012 – a period of two months. 

Regulations may be published by the Minister of Health in terms of section 22G of the Medicines and Related Substances Act No. 101 of 1965, as amended ("the Medicines Act") in order to control the prices of medicines and Scheduled substances. These Regulations, when initially published, were challenged in the courts but ultimately have prevailed. The amendments that are now proposed to the single exit pricing regulations are designed to address primarily the meaning, scope, ambit and content of the prohibition contained in section 18A of the Medicines Act concerning the supply of medicines in terms of a rebate system or any other incentive scheme. The provisions of section 18A of the Medicines Act contain various terms that are not defined in either the Medicines Act or in regulations pursuant to the Medicines Act. Simply put, section 18A provides that: "No person shall supply any medicine according to a bonus system, rebate system or any other incentive scheme."

Conceivably, the provisions of section 18A are very broad and may apply to a number of arrangements or transactions currently in place in the market place. However section 18A is tethered, by its own language, to the supply of medicine. Therefore, the number of transactions to which section 18A may be applicable may be limited as such transactions, when they have nothing to do with the supply of medicine, fall outside of the provisions of section 18A. All of that, however, is about to change.

The amendments that are proposed to the single exit pricing regulations expand significantly the provisions of section 18A by adding content to the terms in section 18A such as "bonus system", "rebate system", "discounts" and "other incentive scheme". Careful consideration will therefore have to be given to existing transactions within the context of the amendments proposed to the single exit price regulations on the assumption that these amendments will eventually pass, as they currently stand, into law. One of the most important amendments that is proposed in the draft regulations deals with the issue of a definition of "[b]onus system, rebate system or any other incentive scheme". This definition means any one of:

  • unacceptable advertising fees;
  • unacceptable credit payment;
  • unacceptable data fees;
  • unacceptable fees paid to induce and/or encourage biased sale of a particular medicine or schedule product;
  • discounts;
  • formulary listing payments;
  • kickbacks and perverse incentives;
  • loyalty fees or similar fees or prizes or rewards;
  • unacceptable marketing fees and/or co-marketing fees;
  • shelf space fees;
  • directors' fees, honoraria and similar compensation paid to a healthcare professional or any person who is in a position to potentially influence medicine choice, where such professional or other person actually do not perform any services or work for which s/he is purportedly being remunerated;and/or
  • fees, enrichment of or benefit provided to a healthcare professional, administrative staff or any business enterprise or healthcare establishment in the healthcare sector which fee, enrichment or benefit is provided on the understanding that the health establishment or professional will give preference to, or encourage the purchase, sale, prescription, dispensing, use or recommendation of a particular medicine or medicines in return for such fee, enrichment or benefit.

The abovementioned definition forms the heart of the amendments proposed in the draft regulations. A number of secondary definitions are also included in the proposed amendments including "[b]usiness enterprise" and a lengthy definition concerning what is or is not a "discount".

The amendments also intend to introduce specific definitions for the terms "end dispensers", "end user", "logistical services" and "logistics fee cap". These definitions are important in light of the introduction of a proposed revised definition of "Single Exit Price", which shifts from the current definition concerning the application of a logistics fee and a price determined by the manufacturer or importer of a medicine to the "ex-manufacturer price determined by the manufacturer or importer of a medicine or scheduled substance in terms of these regulations combined with the logistics fee and VAT and is the price of the lowest unit of the medicine or scheduled substance within a pack multiplied by the number of units in the pack. The Director-General must confirm the correctness of the SEP calculation prior to communication to the public;".

The reference in the proposed definition of "Single Exit Price" to the logistics fee must now be understood with reference to what services are intended to be included in the calculation of the logistics fee – bearing in mind that the logistics fee is also redefined with reference to three components that now form the single exit price of a medicine. These components are the price determined by the manufacturer, the logistics fee "which is determined through negotiation between the manufacturer or importer and the logistics service provider of their medicines or scheduled substances" and value added tax.

The logistics services that are to be taken into account are proposed as an exhaustive list - contained in an amended definition of "logistical services". The services refer to expressly in the proposed amendments are the following:

  • Receiving of medicines or scheduled substances;
  • Warehousing of medicines or scheduled substances;
  • Proper inventory control and rotation;
  • Taking orders from end dispensers;
  • Delivery of orders to end dispensers;
  • Provision of emergency deliveries to end dispensers where required;
  • Proper record keeping;
  • Batch tracking and tracing;
  • Ability to maintain cold chain storage and distribution where necessary;
  • Returning products to manufacturers when required; and
  • Having and operating a debtor's control system which conforms to accepted accounting norms."

The provision of logistical services also has to be considered in light of the definitions of rebate, incentive and discount schemes that are identified in the proposed regulations. In addition, logistical services may only be provided by logistics service providers who, in turn, must be licensed to provide such services in terms of section 22C of the Medicines Act.

Subsequent proposed amendments to the regulations also deal with:

  • the manner in which the Single Exit Price for medicines is to be reflected on medicine containers;
  • the adjustment of the single exit price in terms of independent reviews of the prices determined by the manufacturer or logistics fee components of the single exit price by the regulatory authorities;
  • the increase of the single exit price annually, more particularly, the criteria that the Minister of Health is to take into account before allowing any increases to a single exit price. Those criteria include the average consumer price index for the preceding year, foreign exchange rates, "international pricing information", comments from interested and affected parties and "the need to insure the availability, affordability and quality of medicines and scheduled substances in the Republic.";
  • exemptions and exclusions to the increase of the single exit price which are intended to be provided only with reference to the criteria that the Minister may use to determine such an exemption or exclusion; and
  • powers afforded to the Director-General of the Department of Health to obtain, from a range of persons concerned with the supply of medicine, information relating to the pricing of that medicine. This is an important change in the powers afforded to the Director-General especially in relation to the amendment of the definitions and introduction of the definition of "bonus system, rebate system or any other incentive scheme" as the power to police the introduction of such schemes is now afforded to the Director- General within the context of the single exit price regulations – a power that rests within the amendments proposed to regulation 22 of the single exit price regulations.

The one difficulty faced by the proposed amendments, as they currently stand, more particularly, the definitions of "bonus system, rebate system or any other incentive scheme" and "discounts" is the infection of these definitions by vague terms and rambling sentences that ultimately cause more problems from an interpretation point of view than legislative solutions. Consequently, the proposed amendments may be too vague to pass constitutional challenge and may have to be revisited in their entirety before they are introduced into law. This having been said, in so far as the public remain passive about the issues contained in the draft regulations, then there is no reason why the regulations should not pass into law in their current format.

One aspect of the proposed regulations is clear: the end to transactions, currently in place, dealing with any particular aspect otherwise affected by the regulations. The full extent of the effect of the regulations, as amended, especially within the context of the Medical Schemes Act No. 131 of 1998, as amended ("the MSA"), will have to be seen and tested. Unfortunately, the writer's view remains that the proposed amendments to the single exit price regulations are too broad and too vague to be enforced especially within a medicines and Scheduled substances environment that is fundamentally split between two economic realities: the one is the manner in which medicines and Scheduled substances move through the supply chain when medical schemes and associated parties are involved and the other when these commodities move through ordinary supply chains without the interference of the provisions of the MSA such as formulary listings, managed healthcare principles and applicable treatment protocols and algorithms. Unfortunately, medical schemes only derive savings from the supply of medicines by the application of principles especially created in terms of the MSA to allow medical schemes to control costs of medicines and the supply of Scheduled substances. With the invasion of the single exit price regulations into the medical schemes arena, many of the managed healthcare principles that are currently applicable to the supply of medicines may possibly be compromised and struck down by the amendments. Therefore, the proposed amendment may operate to render medicines, supplied within the medical schemes environment, susceptible to increases, alternatively, falling off medical scheme formularies to the disadvantage of medical scheme members.

As with any aspect of healthcare regulation, the debate about whether or not intensive regulation is preferable to promote the interests of the South African healthcare consumer, is contentious - especially in so far as the costs of medicines and the current structuring of the medicines supply chain in the Republic are concerned.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions